Serum and CSF alpha-synuclein levels do not change in COVID-19 patients with neurological symptoms
Víctor Antonio Blanco-Palmero, Francisco Javier Azcárate-Díaz, Mariano Ruiz-Ortiz, María Isabel Laespada-García, Pablo Rábano‐Suárez, Antonio Méndez-Guerrero, M. Aramendi-Ramos, J. L. Eguiburu, Alfredo Pérez‐Rivilla, Álvaro Marchán-López, Marcos Rubio‐Fernández, Eva Carro, J. González de la Aleja
Topics & Concepts
NeurologyAlpha-synucleinMedicineEncephalopathyCerebrospinal fluidMyoclonusNeuroradiologyParkinsonismCoronavirus disease 2019 (COVID-19)Alpha (finance)Downregulation and upregulationInternal medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseasePediatricsParkinson's diseaseAnesthesiaPsychiatrySurgeryBiologyBiochemistryInfectious disease (medical specialty)Construct validityPatient satisfactionGeneLong-Term Effects of COVID-19Neuroinflammation and Neurodegeneration MechanismsCOVID-19 and Mental Health